Blood test maker and epigenetics company VolitionRx is appointikng medical services company Diagnostic Oncology CRO to lead U.S. clinical tests of VolitionRx's Nu.Q product line, with the hopes of receiving FDA clearance.
Diagnostic Oncology CRO will conduct research and clinical tests of Nu.Q NETs and Nu.Q blood tests to determine the test's clinical utility for cancer and sepsis. The tests will be administered at several U.S. sites, according to the Aug. 8 VolitionRx news release.
"We're delighted to be working with Volition, providing support and acting as the company's regulatory and clinical affairs team in the U.S. Volition's technology has the potential to significantly improve patient outcomes in those diagnosed with sepsis or cancer, said Diagnostic Oncology CRO CEO and President Thomas Soriano. "Through the conduct of Volition's clinical validation studies, we hope to validate a broad range of potential Nu.Q products and support Volition's U.S. commercialization strategy."